Gilmartin Capital is a venture capital firm that invests in entrepreneurs targeting platforms that influence large or underserved diseases, technologies that accelerate and expand scientific discovery, and solutions that impact the cost, site and delivery of care. The firm focuses on opportunities beyond proof of concept in the Medical Device, Life Science Tool, Diagnostic and Digital Health sectors.

Gilmartin Capital

We invest in entrepreneurs targeting platforms that influence large or underserved diseases, technologies that accelerate and expand scientific discovery, and solutions that impact the cost, site and delivery of care. Our focus is on opportunities that are beyond proof of concept and poised for more significant development and growth in the Medical Device, Life Science Tool, Diagnostic and Digital Health sectors. 

The investing landscape is long on capital and short on insight. Our value extends beyond capital. We possess extensive domain expertise in areas such as strategy, market assessment, and capital markets advisory. Our passion is to avail our experience and network to help you solve problems, drive scientific discovery, help patients and grow. For over two decades, we have amassed a propriety expert network consisting of key opinion leaders across multiple therapeutic verticals and technical specialties, and best-in-class operators in various operational, scientific, and financial areas.  In fact, the majority of our fund capital comes from operators like you. The founding partners have decades of experience analyzing and advising healthcare technology companies. We do the math! We want to help you advance your vision.

Gilmartin Capital LLC

Gilmartin Capital is pleased to announce our participation in Kestra Medical Technologies, Inc.’s oversubscribed financing. We are excited to partner with Kestra in protecting at-risk patients with its modern Wearable Cardioverter Defibrillator (WCD). Kestra’s differentiated ASSURE cardiac recovery system can disrupt the existing $1 billion WCD market, catalyze market acceleration and play an increasingly important role in heart recovery. 

Official press release: https://lnkd.in/g9DqcBXQ

Gilmartin Capital is pleased to announce our participation in the Series G financing for Insightec. We are excited to partner with Insightec to expand incisionless neurosurgery and improve care for patients suffering from movement disorders, such as essential tremor and Parkinson’s disease.
 
Much is known about the function and electrical conductivity of the heart, but the brain remains more mechanistically elusive. We believe the intersection of targeted brain mapping paired with precise, incisionless surgery has great promise in the future.

Official press release: https://lnkd.in/gfT2cgNs

Gilmartin Capital is excited to welcome Stephen K. to the firm as an Associate. Stephen joins us from Bain where he worked in the firm’s private equity due diligence practice in the area of Healthcare. We are excited for Stephen to continue our mission to help entrepreneurs solve problems, drive scientific discovery, help patients and grow.

GILM

COM:GILMARTINCAP

Gilmartin Capital